Lucid Diagnostics Inc.
For the period ended Dec 31, 2025. Filed Mar 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 25, 2026
LUCD$0.40-4.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
| · · Years Ended December 31, · | ||||||||
|---|---|---|---|---|---|---|---|---|
| · · 2025 · · · 2024 · | ||||||||
| Cash flows from operating activities | | | | | | | | |
| Net loss | | $(58,010) | | $(45,529) | ||||
| | | | | | | | | |
| Adjustments to reconcile net loss to net cash used in operating activities | | | | | | | | |
| Depreciation and amortization expense | | | 872 | | | | 1,167 | |
| Stock-based compensation - Lucid Diagnostics Inc. 2018 Equity Plan | | | 4,387 | | | | 4,183 | |
| Stock-based compensation - PAVmed Inc. 2014 Equity Plan | | | 104 | | | | 351 | |
| Change in fair value - Senior Secured Convertible Note | | | 7,656 | | | | (5,394) | |
| Debt extinguishment loss - Senior Secured Convertible Note | | | — | | | | 5,167 | |
| Amortization of common stock payment for vendor service agreement | | | 234 | | | | 346 | |
| Equity issuance cost extinguishment | | | 1,078 | | | | — | |
| Changes in operating assets and liabilities: | | | | | | | | |
| Accounts receivable | | | (601) | | | — | | |
| Prepaid expenses and other current assets | | | (1,841) | | | 1,159 | | |
| Accounts payable | | | (270) | | | 96 | | |
| Accrued expenses and other current liabilities | | | (110) | | | (1,012) | ||
| Due To: PAVmed Inc. - operating expenses, employee related costs, MSA Fee | | | 16 | | | | (4,674) | |
| Net cash flows used in operating activities | | | (46,485) | | | (44,140) | ||
| | | | | | | | | |
| Cash flows from investing activities | | | | | | | | |
| Purchase of equipment | | | (197) | | | (296) | ||
| Purchase of intellectual property from PAVmed Inc. | | | — | | | | (350) | |
| Net cash flows used in investing activities | | | (197) | | | (646) | ||
| | | | | | | | | |
| Cash flows from financing activities | | | | | | | | |
| Proceeds – issue of preferred stock | | | — | | | | 29,798 | |
| Proceeds – issue of common stock - Registered Direct Offering, net of fees | | | 14,935 | | | | — | |
| Proceeds – issue of common stock - Confidentially Marketed Public Offering, net of fees | | | 43,171 | | | | — | |
| Proceeds – issue of Senior Secured Convertible Notes | | | 360 | | | | 21,615 | |
| Payment – repayment of Senior Secured Convertible Note | | | — | | | | (3,616) | |
| Proceeds – issue of common stock – At-The-Market Facility | | | 274 | | | | — | |
| Proceeds – exercise of stock options | | | 17 | | | | 4 | |
| Proceeds – issue common stock – Employee Stock Purchase Plan | | | 272 | | | | 447 | |
| Net cash flows provided by financing activities | | | 59,029 | | | | 48,248 | |
| | | | | | | | | |
| Net increase (decrease) in cash | | | 12,347 | | | | 3,462 | |
| Cash, beginning of period | | | 22,358 | | | | 18,896 | |
| Cash, end of period | | $34,705 | | | $22,358 | | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.